<DOC>
	<DOCNO>NCT00294723</DOCNO>
	<brief_summary>This trial conduct North America ( United States America ( USA ) Mexico ) . The trial design evaluate effect treatment liraglutide versus glimepiride subject type 2 diabetes . The trial 52-week randomise , double-blind trial period plus 52-week open-label extension ( week 104 ) follow additional 156-week continue open-label extension . The total duration treatment period plan 260 week ( 5 year ) .</brief_summary>
	<brief_title>To Evaluate Effect Liraglutide Versus Glimepiride ( AmarylÂ® ) Haemoglobin A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes TTreatment diet/exercise half maximal dose oral antidiabetic drug alone least 2 month Diet/exercise treat subject HbA1c 7.0 % 11 % , inclusive OAD ( oral antidiabetic drug ) treat subject HbA1c 7.0 % 10 % , inclusive Body Mass Index ( BMI ) less equal 45 kg/m^2 Treatment insulin last 3 month , except shortterm treatment intercurrent illness Treatment drug could interfere glucose level ( besides use single antidiabetic compound ) Any serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>